Adalta Ltd. · ASX:1AD
Adalta — Investor Presentation (May 2019)
24 slides from Adalta's investor presentation, May 23, 2019
Slide 1: AdAlta Investor Presentation May 2019
For personal use only AdAlta Investor Presentation May 2019 Sam Cobb, CEO and Managing Director AdAlta Limited (ASX:1AD) s.cobb@adalta.com.au
Slide 2: Disclaimer
Disclaimer For personal use only Investment in AdAlta is subject to investment risk, including possible loss of income and capital invested. AdAlta does not guarantee any particular rate of return or performance, nor do they guarantee the repayment of capital. This presentation is not an offer or in
Slide 3: AdAlta (1AD) investment summary
AdAlta (1AD) investment summary For personal use only AdAlta Limited (ASX:1AD) is an Australian listed drug discovery and development company generating a promising new class of protein therapeutics, known as i-bodies, for treating a wide range of human diseases Investment highlights AD-214 targetin
Slide 4: Financial position
Financial position For personal use only Key financial details Share price performance (last 12 months) ASX code 1AD 0.40 1.0 Share price (21 May 2019) AUD$0.185 0.35 0.8 Market capitalisation AUD$21.76m 0.30 Share Price ($) Volume (’000) 0.25 0.6 Shares on issue 117,604,523 0.20 0.4 Options on issu
Slide 5: Management in place delivering on milestones
Management in place delivering on milestones For personal use only Sam Cobb Founding CEO and Managing Director Sam is the founding CEO of AdAlta and has over fifteen years’ experience in business development and commercialisation of early stage scientific technologies. Extensive experience in raisin
Slide 6: Board with track record
Board with track record For personal use only Sam Cobb: Founding CEO and Director Dr John Chiplin: Independent Director Founding CEO of AdAlta and extensive experience CEO of investment company, NewStar Ventures in raising equity, contract and grant funding Managing Director of acquired antibody com
Slide 7: World class Scientific Advisory Board
World class Scientific Advisory Board For personal use only Internationally recognised with proven track record of drug development Dr Mick Foley, AdAlta CSO John Westwick, pulmonary drug Expert in phage display discovery and development NIH, NHMRC, ARC, Gates funding Over 14 years experience at Nov
Slide 8: Market opportunity for IPF
Market opportunity for IPF For personal use only Idiopathic Pulmonary Fibrosis (IPF) is an irreversible, unpredictable and incurable disease THE STATISTICS People living with IPF 300,000 People die from IPF every year 40,000 Median length of survival after IPF diagnosis 3.8 years 8
Slide 9: AD-214 novel treatment for fibrosis
AD-214 novel treatment for fibrosis For personal use only AdAlta’s lead i-body has demonstrated in vivo activity in the Bleomycin mouse model AdAlta’s i-body reduces collagen content and inflammatory cell infiltration and demonstrates a similar architecture to that of the normal lung Normal IPF lung
Slide 10: AD-214 has broad application in treating fibrosis
AD-214 has broad application in treating fibrosis For personal use only AdAlta data suggests that AD-214 can improve fibrosis across a range of fibrotic diseases LUNG: Idiopathic Pulmonary Fibrosis EYE: Wet-Age Related Macular Degeneration Lung Eye Liver LIVER: NASH IPF Wet-AMD & PVR NASH & CIRRHOSI
Slide 11: Global market interest in fibrosis treatments
Global market interest in fibrosis treatments For personal use only Fibrosis assets acquired at an early stage – typically based on Phase I results Date Company Target Acquired by Deal value (US$) Deal commentary Sep-18 Samumed SM04646 United $10m upfront, plus Undergoing Phase I, USA rights Therape
Slide 12: AD-214 development: key milestones
AD-214 development: key milestones For personal use only 2019 2020 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Manufacturing Dosing & PK studies Toxicology studies Phase I SAD/MAD 12
Slide 13: i-body platform
i-body platform For personal use only Diverse library of 20 billion Screening expertise in Identification and long loop human proteins multiple formats characteristion to lead candidate 13
Slide 14: AdAlta business model – strategy to create value
AdAlta business model – strategy to For personal use only create value Targeting at least 1-2 partnership agreements with upfront payments (and Long loop that future milestones and royalties) within the enables access Pharma & next 12 months to novel drug targets biotech partnerships Revenues: Upfro
Slide 15: AdAlta pipeline
AdAlta pipeline For personal use only IND Class of Discovery Preclinical Manufacturing enabling Phase I Target Target studies Idiopathic Pulmonary CXCR4 GPCR Fibrosis AD-214 Other fibrotic CXCR4 GPCR i-body discovery engine indications Novel Shark antibody discovery MCP-1 ligand pocket Ion i-body di
Slide 16: Market benchmarks
Market benchmarks For personal use only PRODUCT Sep-15 acquired by Roche Aug-15 acquired by BMS US$105m + US$475m US$150m + US$1.25b milestones phase I asset milestones phase IIa asset upfront $ milestones PLATFORM $ $ royalties May -17 with AZ July-17 with Sanofi US$58m upfront + US$2.1b €31m upfro
Slide 17: 2018: significant achievements
2018: significant achievements For personal use only ✓ Orphan Drug Designation (US FDA) of AdAlta i-body for treatment of IPF ✓ Completion of additional pre-clinical animal models in diseases of the lung, kidney, skin; strengthening broad anti-fibrotic data package of anti-CXCR4 i- body ✓ Publicatio
Slide 18: Expected news flow
Expected news flow For personal use only H1 2019: – Complete manufacturing including materials for tox program – Update on i-body pipeline development – Publish i-body ½ life and eye fibrosis data – Preliminary non-human primate data with AD-214 H2 2019 – 4 week NHP toxicology study – Partnership an
Slide 19: Capital Raise
For personal use only Capital Raise May 2019 19
Slide 20: Capital Raising Summary
Capital Raising Summary For personal use only AdAlta is conducting a A$7m capital raising that will assist in funding the Company’s pre-clinical and clinical programs over the next 18 months: – AD-214 pre-clinical studies in fibrosis and safety in non-human primates – AD-214 Phase I trial – Expansio
Slide 21: Timetable (indicative)
Timetable (indicative) For personal use only Trading halt Tuesday 21 May Offer announced, lodge Entitlement Offer Prospectus with ASX and company Thursday 23 May resumes trading Ex date for Entitlement Offer Monday 27 May Record date for Entitlement Offer Tuesday 28 May Settlement of New Shares issu
Slide 22: Use of proceeds AU$7m
Use of proceeds AU$7m For personal use only Use of proceeds AU$m KEY ASSUMPTIONS Manufacturing (GMP only) $3.4 GLP Toxicology studies $0.6 **Includes R&D Tax refund Phase 1 studies $3.0 of ~$6.0m Pipeline Build $1.7 Additional funds would be Working Capital $3.8 used to scale pipeline build Capital
Slide 23: AdAlta Limited (ASX:1AD) Summary
AdAlta Limited (ASX:1AD) Summary For personal use only AD-214 has significant pre-clinical validation demonstrating broad anti-fibrotic and anti- inflammatory effects as well as safety. Manufacturing on track with AD-214 set to be in clinic by Q1 2020 Initial focus on treating Idiopathic Pulmonary F
Slide 24: Contact us
For personal use only Contact us: Sam Cobb, CEO s.cobb@adalta.com.au www.adalta.com.au 24